Kaposi Sarcoma in case of solid organ transplantation
Kaposi sarcoma (KS) is a soft tissue cancer that is related to several intrinsic and environmental factors. In the general population, KS is an extremely rare tumor, however, the risk of its development is substantially increased in immune compromised patients including patients with acquired immune deficiency syndrome (AIDS) and solid organ recipients. Genetic predisposition, seropositivity for human herpes virus type HHV, and increased HHV prevalence in the general population are some proposed factors for the development of KS. Middle East is reported as a highly prevalent region for the incidence of post-transplant KS, reports from Saudi Arabia, Egypt and Turkey indicate a high incidence of this disease. Kaposi sarcoma was first described by Moritz Kaposi in the 1870, the disease was a medical curiosity in Europe and the United States until the acquired immunodeficiency syndrome was recognized in 1981.
Related Conference of Kaposi Sarcoma in case of solid organ transplantation
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Kaposi Sarcoma in case of solid organ transplantation Conference Speakers
Recommended Sessions
- Cyclosporine
- Drug Delivery in Transplantation
- Heart transplant
- Immunosuppressant
- Kaposi Sarcoma in case of solid organ transplantation
- Kidney transplant
- Lung transplant
- Medicine - Surgery
- Organ Donation
- Organ Rejection
- Organ Transplantation
- Organ Transplantation Market to Ascent Exponentially
- Skin & Tissue Grafting
- Stem Cell Transplantation
- Transplant Survival and Transplant Living
- Transplantation Special legal and Ethical problems
- Trends in Organ Transplantation
Related Journals
Are you interested in
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)

